SOMERSET
GenericsSOMERSET is a generic drug manufacturer focused on Cardiovascular, Ophthalmology, Neurology.
SOMERSET's Key Drugs
SOMERSET's core commercial portfolio centers on BRIMONIDINE TARTRATE AND TIMOLOL MALEATE, CALCIUM CHLORIDE 10%, spanning Cardiovascular and Ophthalmology — its most strategically important drugs approved in the last 15 years.
SOMERSET's Recent FDA Approvals
New NDA/BLA approvals for SOMERSET over the last two years — novel drugs only, excluding generics and label supplements.
SOMERSET's Therapeutic Areas
SOMERSET's approved drugs and pipeline span 3 therapeutic areas, led by Cardiovascular and Ophthalmology, across 0 biologic and 2 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
SOMERSET's Top Competitors
SOMERSET's closest competitors by therapeutic-area and drug-target overlap include Novartis, UPJOHN, and AbbVie. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
SOMERSET Pipeline Snapshot
Active clinical trials for SOMERSET across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • BRIMONIDINE TARTRATE AND TIMOLOL MALEATE leads revenue
- • 2 key drugs tracked
Trial Catalysts
- • Cardiovascular pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Discontinued (0)
Company Info
- First Approval
- 2006-02-27
- Latest
- 2026-05-20
- Applications
- 20